Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death

Cell Death and Differentiation

Volumn 12, Issue 6, 2005, Pages 627-636

  Moehring, A ^a   Wohlbold, L ^a   Aulitzky, W E ^b   van der Kuip, Heiko ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Bcr Abl kinase; CML; Imatinib mesylate (STI571, Gleevec ); Poly(ADB ribose) polymerase (PARP)

Indexed keywords

BCR ABL PROTEIN; CASPASE; IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE);

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL LINE; CELL PROTECTION; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOSINE DIPHOSPHATE; ANIMALS; ANNEXIN A5; APOPTOSIS; CELL LINE; CELL MEMBRANE PERMEABILITY; DNA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FUSION PROTEINS, BCR-ABL; HUMANS; INTRACELLULAR MEMBRANES; MICE; MITOCHONDRIA; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; PYRIMIDINES; SIGNAL TRANSDUCTION;

RICKETTSIA SP. PAR;

EID: 20044395846     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401608     Document Type: Article

References (52)

1. Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293
2. Chopra R, Pu QQ and Elefanty AG (1999) Biology of BCR-ABL. Blood Rev. 13: 211-229
3. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE and McCubrey JA (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18: 189-218
4. McLaughlin J, Chianese E and Witte ON (1987) In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA 84: 6558-6562
5. Daley GQ and Baltimore D (1988) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. USA 85: 9312-9316
6. Lugo TG and Witte ON (1989) The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol. Cell. Biol. 9: 1263-1270
7. Verfaillie CM, McCarthy JB and McGlave PB (1992) Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J. Clin. Invest. 90: 1232-1241
8. Gordon MY, Dowding CR, Riley GP, Goldman JM and Greaves MF (1987) Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 328: 342-344
9. Bazzoni G, Carlesso N, Griffin JD and Hemler ME (1996) Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest. 98: 521-528
10. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ and Jones RJ (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83: 2038-2044
11. Laneuville P, Timm M and Hudson AT (1994) Bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. Cancer Res. 54: 1360-1366
12. Sanchez-Garcia I and Martin-Zanca D (1997) Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J. Mol. Biol. 267: 225-228
13. van der Kuip H, Goetz AW, Miething C, Duyster J and Aulitzky WE (2001) Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis. Blood 98: 1532-1541
14. van der Kuip H, Moehring A, Wohlbold L, Miething C, Duyster J and Aulitzky WE (2004) Imatinib mesylate (STI571) prevents the mutator phenotype of BcrAbl in hematopoietic cell lines. Leuk. Res. 28: 405-408
15. Kurzrock R, Kantarjian HM, Druker BJ and Talpaz M (2003) Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann. Intern. Med. 138: 819-830
16. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2: 561-566
17. Oetzel C, Jonuleit T, Gotz A, van der Kuip H, Michels H, Duyster J, Hallek M and Aulitzky WE (2000) The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin. Cancer Res. 6: 1958-1968
18. Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S and Bhalla KN (2000) CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 96: 2246-2253
19. Goetz AW, van der Kuip H, Maya R, Oren M and Aulitzky WE (2001) Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells. Cancer Res. 61: 7635-7641
20. Dan S, Naito M and Tsuruo T (1998) Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell Death Differ. 5: 710-715
21. Okada M, Adachi S, Imai T, Watanabe K, Toyokuni SY, Ueno M, Zervos AS, Kroemer G and Nakahata T (2004) A novel mechanism for imatinib mesylateinduced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. Blood 103: 2299-2307
22. D'Amours D, Desnoyers S, D'Silva I and Poirier GG (1999) Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 342: 249-268
23. Di Lisa F, Menabo R, Canton M, Barile M and Bernardi P (2001) Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J. Biol. Chem. 276: 2571-2575
24. Virag L, Salzman AL and Szabo C (1998) Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death. J Immunol. 161: 3753-3759
25. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG, Dawson TM and Dawson VL (2002) Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297: 259-263
26. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM and Kroemer G (1999) Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397: 441-446
27. Soldatenkov VA and Potaman VN (2004) DNA-binding properties of poly(ADP-ribose) polymerase: a target for anticancer therapy. Curr Drug Targets 5: 357-365
28. Kraus WL and Lis JT (2003) PARP goes transcription. Cell 113: 677-683
29. Quesada P, Malanga M, Di Meglio S, De Lorenzo S, Fabbrocini A, Garbi C, Bianco AR and Pepe S (2003) Recombinant IFN-alpha2b treatment activates poly (ADPR) polymerase-1 (PARP-1) in KB cancer cells. Eur. J. Cancer 39: 2103-2109
30. Southan GJ and Szabo C (2003) Poly(ADP-Ribose) polymerase inhibitors. Curr. Med. Chem. 10: 321-340
31. Beneke S, Diefenbach J and Bürkle A (2004) Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int. J. Cancer 111: 813-818
32. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295: 139-145
33. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA and Zigler AJ (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932
34. von Bubnoff N, Schneller F, Peschel C and Duyster J (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359: 487-491
35. Skorski T, Bellacosa. A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN and Calabretta B (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16: 6151-6161
36. Woessmann W and Mivechi NF (2001) Role of ERK activation in growth and erythroid differentiation of K562 cells. Exp. Cell Res. 264: 193-200
37. Ame JC, Jacobson EL and Jacobson MK (2000) ADP-ribose polymer metabolism. In From DNA damage and Stress Signaling to Cell Death: Poly(ADP-ribosyl)ation reactions, de Murcia G, Shall S (eds). (New York: Oxford University Press) pp. 1-34
38. Burkle A (2001) Physiology and pathophysiology of poly(ADP-ribosyl)ation. BioEssays 23: 795-806
39. Alano CC, Ying W and Swanson RA (2004) Poly(ADP-ribose) polymerase-1mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition. J. Biol. Chem. 279: 18895-18902
40. Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, Tefferi A and Kaufmann SH (2002) Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99: 664-671
41. Berger NA (1985) Poly(ADP-ribose) in the cellular response to DNA damage. Radiat. Res. 101: 4-15
42. Hong SJ, Dawson TM and Dawson VL (2004) Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol. Sci. 5: 259-264
43. Arnoult D, Gaurne B, Karbowski M, Sharpe JC, Cecconi F and Youle RJ (2003) Mitochondrial release of AIF and EndoG requires Gaspase activation downstream of Bax/Bak-mediated permeabilization. EMBO J. 22: 4385-4399
44. Penninger JM and Kroemer G (2003) Mitochondria, AIF and caspases - rivaling for cell death execution. Nat Cell Biol. 5: 97-99
45. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y and Ziv Y (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677
46. Fukuchi K, Watanabe H, Tomoyasu S, Ichimura S, Tatsumi K and Gomi K (2000) Phosphatidylinositol 3-kinase inhibitors. Wortmannin or LY294002, inhibited accumulation of p21 protein after irradiation by stabilization of the protein. Biochim. Biophys. Acta. 1496: 207-220
47. Staal SP (1987) Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. USA 84: 5034-5037
48. Vivanco I and Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2: 489-501
49. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296: 1655-1657
50. Pear WS (1998) Efficient and rapid induction of a chronic myelogenous leukemia- like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92: 3780-3792
51. Ogura M, Morishima Y, Ohno R, Kato Y, Hirabayashi N, Nagura H and Saito H (1985) Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 66: 1384-1392
52. Jonuleit T, van der Kuip H, Miething C, Michels H, Hallek M, Duyster J and Aulitzky WE (2000) Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood 96: 1933-1939